Inhibrx Biosciences Inc. Company Profile
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences at a glance
Inhibrx Biosciences Inc. (NASDAQ: INBX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in La Jolla, CA. Inhibrx Biosciences is led by Mr. Mark Paul Lappe and employs about 109 people. At a market capitalization of $1.37 billion, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0002007919, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Inhibrx Biosciences do?
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Business description based on the company's public filings.
Company information
- Legal name
- Inhibrx Biosciences Inc.
- Ticker
- NASDAQ: INBX
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Mark Paul Lappe
- Employees
- 109
- Headquarters
- 11025 North Torrey Pines Road, La Jolla, CA, United States
- Phone
- 858 795 4220
- Website
- inhibrx.com
- Market cap
- $1.37B
- SEC CIK
- 0002007919
Companies similar to Inhibrx Biosciences
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MAZEMaze Therapeutics Inc. | 25.88 | -1.41% | $1.44B | vs INBX |
| COAGHemab Therapeutics Holdings Inc. | 30.89 | +7.63% | $1.44B | vs INBX |
| TSHATaysha Gene Therapies Inc. | 4.43 | 0.00% | $1.44B | vs INBX |
| IMCRImmunocore Holdings plc ADR | 29.09 | -1.09% | $1.50B | vs INBX |
| REPLReplimune Group Inc. | 13.04 | -1.21% | $1.23B | vs INBX |
| VORVor Biopharma Inc. | 19.13 | +1.86% | $1.13B | vs INBX |
| IMTXImmatics N.V. | 7.37 | -1.07% | $1.12B | vs INBX |
| MGTXMeiraGTx Holdings plc | 10.50 | -2.96% | $1.01B | vs INBX |